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abstract
PURPOSE The National Cancer Institute (NCI)–Designated Cancer Centers (NDCCs) are active in global oncology
research and training, leading collaborations to support global cancer control. To better understand global
oncology activities led by NDCCs, the NCI Center for Global Health collaborated with ASCO to conduct the 2018/
2019 NCI/ASCO Global Oncology Survey of NDCCs.
METHODS Seventy NDCCs received a two-part survey that focused on global oncology programs at NDCCs and
non–National Institutes of Health (NIH)-funded global oncology projects with an international collaborator led by
the NDCCs. Sixty-seven NDCCs responded to the survey. Data were coded and analyzed by NCI-Center for
Global Health staff.
RESULTS Thirty-three NDCCs (47%) reported having a global oncology program, and 61 (87%) reported
a collective total of 613 non–NIH-funded global oncology projects. Of the NDCCs with global oncology programs,
17 reported that trainees completed rotations outside the United States and the same number enrolled trainees
from low- and middle-income countries (LMIC). Primary focus areas of non–NIH-funded projects were research
(469 [76.5%]) and capacity building or training (197 [32.1%]). Projects included collaborators from 110
countries; 68 of these were LMIC.
CONCLUSION This survey shows that there is a substantial amount of global oncology research and training
conducted by NDCCs and that much of this is happening in LMIC. Trends in these data reflect those in recent
literature: The field of global oncology is growing, advancing scientific knowledge, contributing to building
research and training capacity in LMIC, and becoming a recognized career path. Results of the 2018 Global
Oncology Survey can be used to foster opportunities for NDCCs to work collaboratively on activities and to share
their findings with relevant stakeholders in their LMIC collaborator countries.
J Global Oncol. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Mortality from cancer is on the rise, and by 2020 it is
estimated that almost 70% of cancer cases will be in
low- and middle-income countries (LMIC).1 Global oncol-
ogy research plays a crucial role in understanding causes
and patterns of rare cancers,1,2 assessing novel low-cost
therapies,3,4 addressing cancer health disparities,5 and
studying how interventions can best be implemented in
local communities.6-8 Much of this groundbreaking work
occurs through research and training collaborations
between institutions in high-income countries (HIC) and
LMIC. These collaborations aim to benefit both HIC and
LMIC by building cancer research capacity, sharing and
building research resources and infrastructures that le-
verage data and unique experiences of country partners,
answering questions about cancers and cancer pathways
otherwise under-represented in global research, driving
breakthroughs, and improving health outcomes.2,5,9,10-14
The stated mission of the US National Cancer Institute
(NCI) is that it leads, conducts, and supports cancer
research across the nation to advance scientific
knowledge and help all people live longer, healthier
lives.15 As part of this mission, the NCI supports
71 NCI-Designated Cancer Centers (NDCCs) tasked
with delivering state-of-the-art cancer research and
care.10,16 The NCI’s extramural research portfolio in-
cludes awards to domestic (US) institutions, grants
awarded to foreign institutions, and grants with a US-
based institution and one or more foreign collabora-
tors. In fiscal year 2018 (FY2018), grants awarded to
a foreign institution and grants with one ormore foreign
collaborators made up approximately 11.0% of the
overall NCI FY2018 extramural portfolio.17 The ma-
jority (76.3%) of FY2018 grants with foreign collabo-
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Information on global oncology activities are publicly
available from databases such as the National Institutes of
Health (NIH) World RePORT18 (https://worldreport.nih.gov),
which captures the NCI-funded extramural research port-
folio with foreign collaborations, the International Cancer
Research Partnership database19 (www.icrpartnership.org),
and The GO (Global Oncology) Map20 (www.thegomap.org).
However, there is limited literature detailing the full scope of
global oncology research and training collaborations that are
conducted specifically by NDCCs.21 To address this gap, the
NCI Center for Global Health (CGH) fielded surveys to
NDCCs in 2012,22 2014,23 and 2018 to 201924 to better
understand the landscape of non–NIH-funded global on-
cology activities and to augment known information on global
oncology investments. This analysis focuses on the 2018 to
2019 survey results.
NCI/CGH collaborated with ASCO to develop a survey
module on global oncology programs, representing the first
time that NDCCs have been asked by NCI in a standardized
method about the existence and offerings of the global
oncology programs at their cancer centers. Questionnaire
design for this module was done in coordination with
members of ASCO’s Academic Global Oncology Task
Force, an ASCO Board-appointed body of ASCO members
with expertise in global oncology convened to make rec-
ommendations on ways that ASCO can support global
oncology as an academic discipline. The 2018 to 2019
survey had three key objectives: (1) describe the non–NIH-
funded global oncology activities led by NDCCs in a cen-
tralized resource, (2) identify areas where NDCCs are
working to promote research partnerships and potential
areas for increased collaboration, and (3) use the results to
convene NDCCs focused on global oncology opportunities.
METHODS
Survey Design and Distribution
The survey consisted of two sections: (1) 23 questions
focused on global oncology programs at the NDCCs (ie,
programs that include faculty engagement and training
opportunities in global oncology), and (2) 27 questions fo-
cused on non–NIH-funded global oncology projects (ie,
discrete research or capacity-building/training projects with
international collaborators) led by NDCCs. Responses from
NDCCs could be submitted via an online Google Forms survey
or via an Excel spreadsheet that mirrored the fields in the
online survey. The survey tools are available in the full report.24
The survey was piloted to seven NDCCs in early 2018, and
minor adjustments were subsequently made to clarify in-
tent of some survey questions. The revised survey was sent
to all NDCCs between March and May 2018, with an initial
survey closing date of October 2018. For each NDCC, the
survey was sent to the NDCC Director, Administrator, and
any relevant global oncology contact persons identified by
the NDCC leadership, the NCI Office of Cancer Centers,
ASCO, and NCI/CGH staff.
Project Coding
NDCCs were asked to code projects to one or more project
types (eg, research or capacity building), Common Scientific
Outline (CSO) codes, cancer sites (eg, breast, prostate, and
so on), and project funding source(s). Three NCI/CGH staff
reviewed these codes for agreement with the project title and
abstract and, where appropriate, applied additional codes to
further capture themes that arose in the data set. Two NCI/
CGH staff reviewers coded every project to the new codes,
and a third NCI/CGH reviewer reconciled any discrepancies.
NCI FY2018 Extramural Research Portfolio
The NCI-funded FY2018 international extramural research
portfolio, evaluated by authors R.M.A. and K.D. at NCI/
CGH, has been used as a comparison data set to the 2018
to 2019 Global Oncology Survey data presented in this
article. This portfolio was prepared using NIH’s internal
IMPAC II (Information for Management, Planning, Analysis,
and Coordination) data system and includes any extramural
grant funded by NCI during FY2018 with an international




Understand the global oncology program offerings and projects at National Cancer Institute–Designated Cancer Centers
(NDCCs) in 2018 and 2019.
Knowledge Generated
Thirty-three NDCCs (47%) reported having a global oncology program at their center, and 61 NDCCs (87%) reported
a collective total of 613 non–National Institutes of Health (NIH)-funded global oncology projects. Primary focus areas of
non–NIH-funded projects were research (469 projects [76.5%]) and capacity building or training (197 projects [32.1%]),
and projects included collaborators from 110 countries.
Relevance
Benchmarking global oncology programs and non–NIH-funded global oncology projects at NDCCs provides a more holistic
view of cancer centers’ commitment to global oncology and offers insights on how to grow the field of global oncology.
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Statistical Analysis and Review
Data were analyzed in Microsoft Excel and in Statistical
Analysis Software (SAS). In March 2019, a draft version of
the report was circulated to 70 NDCCs for review (at the
time of the survey there were 70 NDCCs), and additional
data revisions were included in the final report.
RESULTS
A total of 67 NDCCs (96% response rate) responded to the
survey (Table 1).
Global Oncology Programs
Thirty-three of 70 NDCCs (47%) reported having a global
oncology program at their institution, and 27 reported
having a designated program lead. The data in this section
represent the 33 NDCCs that reported having a global
oncology program. NDCCs could self-define as a global
oncology program and, as a result, observed program
structures varied frommore formalized academic programs
to informal groups of interested investigators who conduct
global activities. Top program focus areas included re-
search (24 NDCCs), capacity building and training (15
NDCCs), and LMIC collaboration (15 NDCCs; Table 2).
Codes were on the basis of program descriptions supplied
by NDCCs, and programs could receive more than one
code. Thirteen NDCCs reported having one to 10 faculty
members engaged in global oncology, and 19 NDCCs re-
ported having 11 ormore faculty members engaged in global
oncology. Twenty-two NDCCs reported receiving both ex-
ternal funding support and institutional funding for global
oncology activities. Five NDCCs reported receiving only ex-
ternal funding, and three NDCCs reported receiving only
institutional funding support for global oncology activities.
Twenty-seven NDCCs reported providing an average of 1 to
2 days of global oncology training to trainees. NDCCs re-
ported that trainees (in specialties ranging from medical
oncology to radiology) participated in global oncology
training and had an interest in pursuing global oncology as
a part of their future careers. NDCCs also reported offering
training opportunities to students from LMIC, either through
enrolled opportunities (ie, LMIC students were enrolled in
their programs [17 NDCCs]) or nonenrolled opportunities
(ie, LMIC students participated in capacity-building activ-
ities or clinical observerships [15 NDCCs]).
Non–NIH-Funded Global Oncology Projects
A total of 61 NDCCs (87%) reported having one or more
non–NIH-funded global oncology projects, and 613
non–NIH-funded projects were reported overall.
The number of projects reported per NDCC ranged from
one to 58, with 20 NDCCs reporting 10 or more projects.
Top project focus areas were research (77%) and capacity
building or training (32%). Secondary topics included
cancer screening (8.8%), clinical trials (6.9%), imple-
mentation (6.7%), networks or working groups (5.4%),
cancer registries (3.9%), and pathology (3.4%; Table 3).
Projects could be coded to more than one primary or
secondary focus area. Top CSO codes covered by NDCC
global oncology projects included treatment (40%); biology
(34%); and early detection, diagnosis, and prognosis (31%;
Fig 1). The top three cancer sites reported by NDCCs
following non–site-specific cancers (32%) were breast
(18%), cervix (7%), and stomach or GI (5%).
Non–NIH-funded global oncology projects included col-
laborators from 110 countries spanning seven world re-
gions (East Asia and Pacific: 154 projects, 35 NDCCs;
Europe and Central Asia: 131 projects, 39 NDCCs; Latin
America and the Caribbean: 102 projects, 33 NDCCs;
Middle East and North Africa: 41 projects, 21 NDCCs;
North America: 139 projects, 44 NDCCs; South Asia: 28
projects, 15 NDCCs; and Sub-Saharan Africa: 142 projects,
34 NDCCs; Fig 2). Collaborators came from 42 HIC and 68
LMIC, 16 of which were low-income countries. Sixteen of
the top 30 collaborator countries (ranked by number of
non–NIH-funded projects) were LMIC (Fig 3).
NDCCs reported havingmore than 150 different funders for
their non–NIH-funded global oncology projects. Examples
include institutional funds (within the NDCC, 252 projects),
nonprofit organizations (133 projects), industry (33 pro-
jects), and other funding sources including US government
agencies (non-NIH) and international sources (84 pro-
jects). Funding sources were not provided for 105 projects,
and 34 projects were listed as unfunded.
A full summary report of the 2018 to 2019 Global Oncology
Survey was developed by NCI/CGH and is available on the
NCI Web site.
DISCUSSION
Results of the 2018 to 2019 Global Oncology Survey of
NDCCs describe the scope of global oncology programs
and activities of NDCCs and highlight NDCCs’ commitment
to global oncology beyond NIH-funded grants. Trends in
these data reflect those in recent literature: The field of global
oncology is growing,25 advancing scientific knowledge,26
TABLE 1. Summary of National Cancer Institute–Designated Cancer Center Survey
Responses
Question/Response No. (%)
Does NDCC have a formal global oncology program?
Yes 33 (47)
No 34 (49)
No response 3 (4)
Does NDCC have non–NIH-funded global oncology projects?
Yes 61 (87)
No 6 (9)
No response 3 (4)
Abbreviations: NDCC, National Cancer Institute–Designated Cancer Center; NIH,
National Institutes of Health.
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contributing to building research and training capacity in
LMIC,27,28 and becoming a desired career path.29
A Global Oncology Community
Since the 2012 survey, the number of NDCCs reporting
global oncology activities has grown substantially. Fifty-five
of the (at that time) 68 NDCCs (80.9%) reported global
oncology activities in 2012,22 and in the 2018 to 2019
survey, 65 of 70 NDCCs (92.9%) reported global oncology
activities. Previous surveys did not capture details at the
project level, so it is not possible to compare total projects
reported over time. However, in the 2018 to 2019 survey,
61 NDCCs reported a total of 613 non–NIH-funded pro-
jects. Taken together with the approximately 560 extra-
mural grants with a foreign collaborator led by NDCCs in the
NCI FY2018 extramural research portfolio,17 it is clear that
NDCCs are engaging in substantial global oncology activity.
Growth in the number of NDCCs reporting global oncology
activities is mirrored by the increasing number of global
cancer research publications worldwide.25
Nearly half of all NDCCs report having a global oncology
program. There may be additional NDCCs with faculty
conducting global oncology research, despite not having
a program. Although this information was not captured in
previous surveys, this serves as baseline information for
future tracking of growth in the field of global oncology at
NDCCs.
The survey identified diverse funding sources for global
oncology activities, including external grants, institutional
funding, and funding from other sectors. The diversity of
funding sources shows that a variety of actors are interested
in supporting global cancer research and training. It also
indicates that no single funder can sustain the growing
TABLE 2. National Cancer Institute–Designated Cancer Center Program Themes and Example Program Descriptions
Program Theme Excerpt From Program Description
Core faculty work on global oncology activities “Our research program is a group of investigators and clinicians who work in common to
share effort and initiatives.”
“Our program has quarterly meetings of faculty with a professed interest in global health
in cancer.”
Support for training and research “Our program supports training and research in global oncology.”
“[Our mission] is to provide education, research training, and mentorship for trainees
and early career faculty in LMIC and at our cancer center focused on global cancer
research.”
Collaborations “[Our program] is currently primarily focused around multiple collaborations with
[country] researchers.”
“[Our program] collaborates with international organizations to improve cancer services
for more people worldwide.”
“Our program involves a partnership with multiple universities and medical centers.”
LMIC focus “[Our objective is] to perform innovative research that addresses the disparate burden of
cancer in LMIC.”
“[Our programwill focus on] research, education, and humanitarian efforts in lower- and
middle-income countries.”
“Our program includes engagement with cancer care providers, educators, researchers
and policymakers in several disciplines in several LMIC in Latin America; East Asia;
East, South, and North Africa.”
Abbreviation: LMIC, low- and middle-income countries.
TABLE 3. Non–National Institutes of Health-Funded National Cancer Institute–Designated Cancer Center Project Focus Areas and Example
Project Titles
Project Focus Area* Example Project Title
Capacity building and training “Developing and delivering an oncology nurse training curriculum in Nigeria”
Cancer screening “Untangling the barriers and facilitators of effective screening strategies for cervical cancer in
Guatemala”
Clinical trials “Phase I clinical trial examining the safety of treatment of renal cell carcinoma with diffusing alpha-
emitter radiation therapy”
Implementation “Pediatric radiotherapy training and guideline implementation in low- and middle-income countries”
Cancer registries “Building and evaluating cancer registry capacity in Tanzania”
Pathology “Ultrasound-guided fine needle aspiration training workshop”
Network and working groups CLEHOP (Latin American Hemato-Oncologic Pediatric Diseases Consortium)
*Projects could fall into more than one focus area.
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interest in research in this field, as reflected elsewhere in
the literature.10
Advancing Scientific Knowledge of Cancer
NDCC global activities reflect common global oncology
scientific priority recommendations outlined in the litera-
ture: prioritize research across all areas of the cancer
continuum5,9,30-32 and prioritize research in high-burden
cancers.9,30,31,33,34 NDCC projects were more likely than
NIH-funded FY2018 grants with foreign collaborators to
be coded to cancer control, survivorship, and outcomes
research (CSO code #6).17 Within CSO code #6, one of the
identified global priorities is the need for prioritization of
implementation research.8,35 Although the initial analysis
identified that almost 7% of non–NIH-funded projects had
a secondary focus on implementation research, further
analysis is needed to fully understand how NDCCs are
addressing these stated priority areas.
Most non–NIH-funded global oncology projects from
NDCCs that were cancer site specific addressed breast,




































FIG 1. Non–National Institutes of Health-funded National Cancer Institute–Designated Cancer Center global oncology projects by Common Scientific




FIG 2. Map of non–National Institutes of Health-funded National Cancer Institute–Designated Cancer Center global oncology projects by collaborator
country.
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one-third of NDCCs reported projects that included focus
on childhood cancers. Focus on these cancers aligns with
Global Burden of Disease data36 and may indicate align-
ment of research focus with disease burden.
Contributing to Building Research and Training Capacity
in HIC and LMIC
Collaboration to build research and training capacity,
particularly within LMIC, was a theme seen across NDCC
global oncology activities. Non–NIH-funded global oncol-
ogy projects from NDCCs were nearly twice as likely as NCI-
funded FY2018 projects to include collaborators from LMIC
(a total of 68 LMIC).17 Almost one-third focused on capacity
building or training, ranging from research infrastructure
to human resource and skill training. Of the 33 NDCCs
reporting a global oncology program, the majority reported
providing at least some training in global oncology to their
trainees, more than half reported enrolling trainees from
LMICs, and almost half reported providing capacity-building
opportunities for LMIC counterparts. Building capacity in
LMICs to conduct research strengthens local capacity,
provides increased global research opportunities, and
supports the global cancer research community to advance
scientific knowledge of cancers in all communities.5,27,28
Global Oncology Is a Desired Career Path at NDCCs
Importantly, this survey shows that global oncology is a de-
sired career path at NDCCs. For NDCCs that reported having
a global oncology program, the majority reported having 11
or more faculty engaged in their global oncology program.
This number does not capture faculty involvement at NDCCs
without a global oncology program (see Limitations section).
NDCC trainees who participated in global oncology training
also reported having an interest in pursuing global oncology
as part of their career. Notably, NDCCs that did not have
global oncology training related to pediatric oncology re-
ported an interest among their trainees in receiving such
training in the future. As NDCCs continue to strengthen
training in global oncology, there is an opportunity to develop
increased training and career pathways for specialty
trainees. Building the global oncology workforce is critical
to addressing clinician shortages and to expanding can-
cer research across diverse populations.28,37,38 Academic
careers in global health have unique challenges, such as
limited opportunities for global health research funding,
limited academic advancement, and challenges balancing
research demands abroad with personal lives.39 Developing
new ideas to build out global oncology as an academic
career path will be important for creating a pipeline for future
global oncology researchers and clinicians.28,29,40,41 As these
career paths develop at NDCCs, it will be important to
consider how to craft these programs ethically and equitably
so that they avoid the pitfalls of parachute research and
global health consulting malpractice.42,43 The findings of the
ASCOAcademic Global Oncology Task Force (which include
recommendations in the areas of global oncology training
and mentorship, research, and practice) are expected to be
disseminated in a forthcoming publication.
Strengthening Information Sharing Within the Global
Oncology Community
The 2018 to 2019 Global Oncology Survey of NDCCs is
intended to serve as a centralized resource for NDCCs and
their partners to examine the breadth of global activities
across the NDCC community and to identify potential
collaborations. NDCCs reported some challenges in
amalgamating global oncology data (further articulated in
the Limitations section); as such, it may be helpful to de-
velop community-wide standards for collecting data
and reporting on global oncology programs and projects.
This will assist in more accurate overall reporting and
building the case for supporting NDCC-led global oncology
activities.
This report is intended to be a catalyst and convening tool
for strategic discussions among NDCCs. In addition, the
report can inform the efforts of other stakeholders, such as
ASCO and other oncology societies, to support the pro-
fession, and their members who are interested in this field.
One opportunity will be at the 8th Global Cancer Research
Symposium, a scientific satellite meeting at the 2020 An-
nual Consortium of Universities for Global Health Confer-
ence to be held on April 17, 2020, in Washington, DC. The
Symposium aims to convene individuals working in global
oncology to discuss trends, gaps, and potential collabo-
rations in global cancer research and control.
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FIG 3. Non–National Institutes of Health-funded National Cancer Institute–Designated Cancer Center global oncology projects by collaborator country.
Low- and middle-income countries are shown in orange, and figure includes projects defined as global.
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Limitations
Factors affecting data accuracy and completeness of this
survey are as follows: (1) data were self-reported by NDCCs,
and data completeness was at the discretion of responding
institutions; (2) data may vary depending on who within the
NDCC supplied the information; (3) in some cases, these
data were not held centrally and were difficult for re-
spondents to amalgamate; (4) NDCCs varied in the types of
projects they reported (eg, some NDCCs reported un-
funded work whereas others did not); (5) projects were self-
reported, so it is possible that multiple NDCCs working on
the same or a similar project reported these projects in-
dividually; and (6) the terms “global oncology” and “global
oncology programs” were not defined in the survey be-
cause a current widely accepted definition of global on-
cology does not yet exist.32 Therefore, NDCCs may have
had different understandings of the definition of “global
oncology program,” which may have affected the re-
sponse rate. As a result, data on faculty and trainee en-
gagement in global oncology activities, and the total
number of non–NIH-funded projects, may be under- or
over-reported.
To confirm accuracy of reporting on non–NIH-funded
projects, a subset of projects (61 projects [10%]) was
scanned for potential duplicates within the NIH-funded
portfolio. Of the 61 projects reviewed, two (3.3%) had
received funding from NIH, 55 (89.7%) had not received
funding from NIH, and funding status for four projects
(6.5%) could not be determined. This subanalysis provides
a high level of confidence that most reported projects are
not represented in the NIH portfolio.
In conclusion, the 2018 to 2019 Global Oncology Survey of
NDCCs demonstrates a robust level of global oncology
activities occurring at NDCCs and is the first of its kind to
provide a baseline measurement of the number and types
of NDCC global oncology programs. Understanding the
broad reach of global oncology programs and non–NIH-
funded projects that are ongoing at NDCCs is important
for facilitating collaborations between NDCCS. This report
should serve as a catalyst for strategic discussions on
coordination and investment. The NDCC global oncology
community is growing and has a unique opportunity to
advance scientific knowledge, build research capacity in
HIC and LMIC, and strengthen the global oncology aca-
demic career path at NDCCs. Future iterations of the survey
have the potential to capture greater detail on global on-
cology offerings at NDCCs and align with ongoing priorities
of the NDCC global oncology community.
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